Abstract: The present invention relates to a pharmaceutical product for administration to a patient, the product comprising 4?-cyano-??,??,??-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropiono-m-toluidide, or a pharmaceutically acceptable salt or solvate thereof, in solid dispersion with an enteric polymer having a pKa from 3 to 6, the product further comprising an anti-oestrogen (eg, tamoxifen citrate) and/or an aromatase inhibitor (eg, anastrozole). The invention also relates to a pharmaceutical dose of the drug and anti-oestrogen/aromatase inhibitor provided by such a formulation.

Abstract: The present invention relates to a pharmaceutical product, daily dose or dose regimen comprising an anti-androgen and tamoxifen, wherein the anti-androgen is selected from flutamide, nilutamide, chlormadinone acetate and cyproterone or pharmaceutically acceptable salt or solvate thereof. The invention also relates to a method of providing an anti-androgenic effect and anti-oestrogenic effect in a patient, wherein the anti-oestrogenic effect is provided substantially without causing an additional increase in the levels of circulating androgens.

Abstract: The present invention relates to a pharmaceutical product, daily dose or dose regimen comprising 4′-cyano-&agr;′,&agr;′,&agr;′-trifluoro-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methylpropriono-m-toluidide (compound I) and anastrozole. The invention also relates to a method of providing an anti-anrogenic effect and aromatase inhibition in a patient, wherein the aromatase inhibition is provided substantially without causing an additional increase in the levels of circulating androgens.